Trend Analysis Report on NASDAQ Stocks: (NASDAQ: GERN), (NASDAQ: OCZ)
Geron Corporation (NASDAQ: GERN). California-based BioTime Inc. announced on January 7 that it will buy Geron Corporation’s human embryonic stem cell (hESC) assets, which includes intellectual property, 400 patents and patent applications, and the first ever US Food and Drug Administration-approved Phase I clinical trial of a hESC therapy.
View full press release